Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant FOLFOX after resection for high-risk hepatocellular carcinoma
ChiCTR-IPR-15007509Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease-free survival. Started Apr 2015; status: recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IPR-15007509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007509.